ESOPHAGEAL SQUAMOUS CELL CARCINOMA

This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help shrink tumors in people with locally advanced esophageal cancer. About 42 adults with this type of cancer will receive the combination, then have surgery. The main goal is to see…

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…

This study is for people with advanced esophageal cancer that has gotten worse after standard treatments. It tests new drug combinations, with or without the immunotherapy pembrolizumab and chemotherapy, to see if they can shrink tumors or slow the cancer's growth. About 230 adul…

This study tests new drug combinations, including an antibody-drug conjugate, with the immunotherapy pembrolizumab (with or without chemotherapy) for people with advanced esophageal cancer that cannot be surgically removed or has spread. About 298 participants will join this earl…

This study tests whether adding a precise, high-dose internal radiation treatment (brachytherapy) after standard external radiation, chemotherapy, and the immunotherapy drug nivolumab can help prevent esophageal cancer from coming back. About 60 adults with advanced esophageal sq…

This study tests whether adding itraconazole, a widely used antifungal medication, to standard chemotherapy and radiation can help eliminate more esophageal cancer before surgery. About 78 adults with resectable esophageal or gastroesophageal junction cancer will take itraconazol…

This study tests a new drug called vebrekotuzumab for people with advanced esophageal cancer that no longer responds to initial treatment. The drug is designed to deliver a powerful cancer-killing agent directly to tumor cells, aiming to slow or shrink the cancer. About 104 parti…

This study tests whether adding low-dose or standard radiotherapy to the usual immunotherapy and chemotherapy can help control metastatic esophageal squamous cell carcinoma. About 100 adults with untreated, advanced cancer will be enrolled. The goal is to see if the combination i…

This study tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for people with advanced or returning esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can shrink or control the tumors better than standard care…

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to target a protein called Claudin-1 found on these cancer cells. The main goals are to check the drug's safety, find th…

This study tests whether intensive nutritional support can help patients with locally advanced esophageal cancer that cannot be surgically removed. Participants receive standard chemo-immunotherapy and are randomly assigned to either intensive enteral nutrition or standard care. …

This study tests whether adding the immunotherapy drug adbelimumab to standard chemotherapy and the targeted drug apatinib can help shrink esophageal cancer before surgery. About 35 adults with resectable stage II–IVA esophageal squamous cell carcinoma will receive this combinati…

This study tests a combination of the immunotherapy drug envafolimab and two chemotherapy drugs given before surgery for people with a type of esophageal cancer that can be removed. The goal is to see if this treatment can shrink or eliminate the tumor before the operation. About…

This study tests a new drug called ivonescimab combined with a short course of radiation for people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer and improve survival. The study will e…

This study is testing whether a drug called tislelizumab, when combined with chemotherapy, can help control advanced stomach or esophageal cancer in US racial and ethnic minority patients. About 30 adults who have not had prior treatment for their cancer will receive the drug com…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The main goal is to check safety and find the right dose. About 1,000 participants will join this study t…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced esophageal cancer that has worsened after standard chemotherapy and immunotherapy. About 510 adults will be randomly assigned to receive either I-DXd or a standard chemotherapy chosen by thei…

This early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors…

This early-phase study tests a new drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell cancers (lung, esophagus, skin, and others) that have not responded to standard treatments. About 160 participants will receive the drug to see if it …

This study tests whether adding the drug surufatinib to standard chemotherapy, immunotherapy, and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can keep the cancer from growing for at least two …

This study is testing whether adding the drug ivonescimab (AK112) to standard chemotherapy before surgery can help shrink tumors in people with advanced esophageal cancer. About 45 adults with resectable, locally advanced esophageal squamous cell carcinoma will receive the combin…

This study tests a treatment plan based on a biomarker (CPS score) given before surgery for people with a certain type of esophageal cancer. About 90 adults with resectable, locally advanced esophageal squamous cell carcinoma will receive this tailored neoadjuvant therapy. The ma…

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The goal is to see how the body absorbs and handles the radiation from RAD301, and whether it…

This study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday practice in Germany. It will include about 1,900 adults starting their first palliative therapy. The goal is to unders…